Abstract. Radiomics, the extraction of quantitative data from images, holds promise for noninvasively characterizing tumor phenotypes. Tools like LIFEx have improved the accessibility, transparency, ...

The efficacy of immunotherapy targeting PD-1/PD-L1 in gastric cancer depends on PD-L1 expression levels and the infiltration of immune cells within the tumor microenvironment (TME). Although ...

Abnormal amino acid metabolism supports cancer cell proliferation, invasion, and immune evasion in hepatocellular carcinoma (HCC). Previous research exploring amino acid metabolism in HCC has ...

Antibody–drug conjugates are an emerging treatment of non–small cell lung cancer. Some do not require biomarkers, whereas others require mutations and/or protein expression. New diagnostic ...

An Iranian missile hit the campus of Israel’s Weizmann Institute of Science, destroying many cancer research labs. Researchers mourned the loss of expensive equipment and irreplaceable samples and ...

AbstractPurpose:. Ipilimumab (IPI) improved outcomes for patients with high-risk melanoma compared with IFN-α2b in E1609, a phase III adjuvant trial. We hypothesized that combining candidate immune ...

NCT03642067 was a phase II study evaluating the combination of relatlimab (LAG-3 inhibitor) and nivolumab (PD-1 inhibitor) in patients with previously treated metastatic pMMR colorectal cancer.

The FDA gave accelerated approval to datopotamab deruxtecan (Datroway; Daiichi Sankyo), a TROP-2 targeting antibody–drug conjugate (ADC), for patients with advanced or metastatic EGFR-mutated ...

Major Finding: An intraoperative sequencing workflow provides rapid turnaround of comprehensive molecular profiling of central nervous system (CNS) tumors. Concept: Methylation profile and DNA copy ...

The American Society for Radiation Oncology (ASTRO) issued new guidance on using radiation therapy to treat grade 4 diffuse gliomas, which account for nearly half of malignant brain tumors in adults ...

The NIH will, for now, not cancel additional research grants beyond those that have already been terminated, according to an internal memo from a senior NIH official informing agency staff of the ...

Adding pembrolizumab (Keytruda; Merck) to standard of care improved event-free survival for patients with head and neck squamous-cell carcinoma (HNSCC) in the phase III KEYNOTE-689 study, according to ...